revexepride

Small moleculeexperimental

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2010 (NCT01370863)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COCCCN1CC[C@@H](CNC(=O)c2cc(Cl)c(N)c3c2OC(C)(C)C3)[C@H](O)C1
Mol. weight
425.96 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • revexepride
  • revexepride
  • revexepride
  • spd557
  • spd-557
  • spd-557
  • ssp-002358
  • ssp-002358
  • ssp-002358
  • ssp-002358

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01786876Phase 1Feb 1, 2013Covance, Shire
NCT01472939Phase 2Feb 1, 2012Shire
NCT01415349Phase 1Aug 1, 2011Shire
NCT01370863Phase 2Dec 1, 2010Katholieke Universiteit Leuven, Movetis, Shire
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ShireFor profit4422010
CovanceFor profit1012013
Katholieke Universiteit LeuvenAcademic/Hospital1012010
MovetisFor profit1012010
4 organizations
Page 1 / 1